Covered recipient · General Payments record
TULIN BUDAK ALPDOGAN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$3,811.01
- Reported across 53 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $197.42 | 12 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genmab U.S., Inc. | $53.62 | 3 |
| Genentech USA, Inc. | $31.13 | 2 |
| Incyte Corporation | $30.41 | 2 |
| GlaxoSmithKline, LLC. | $17.94 | 1 |
| Janssen Scientific Affairs, LLC | $17.00 | 1 |
| GENZYME CORPORATION | $16.44 | 1 |
| Lilly USA, LLC | $15.76 | 1 |
| ABBVIE INC. | $15.12 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (12)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.12 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103386707 | CMS |
| Genentech USA, Inc. | $14.27 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133127617 | CMS |
| Genentech USA, Inc. | $16.86 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133127621 | CMS |
| Genmab U.S., Inc. | $18.57 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833131 | CMS |
| Genmab U.S., Inc. | $16.93 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833133 | CMS |
| Genmab U.S., Inc. | $18.12 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833135 | CMS |
| GENZYME CORPORATION | $16.44 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139838797 | CMS |
| GlaxoSmithKline, LLC. | $17.94 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116410469 | CMS |
| Incyte Corporation | $16.88 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141234673 | CMS |
| Incyte Corporation | $13.53 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141245062 | CMS |
| Janssen Scientific Affairs, LLC | $17.00 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078854474 | CMS |
| Lilly USA, LLC | $15.76 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135451184 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.